This protocol applies to acanthosis nigricans (AN) of the skin that develops as a direct consequence of a causative medication. In this setting, identifying the offending agent is the central step in clinical decision-making.
Management focuses on addressing the relationship between the patient and the causative medication. The structured evidence-based regimen — including the specific steps and alternatives for particular drug classes — is available in the full protocol.
Goal: complete resolution of AN within weeksDOI: 10.2147/CCID.S137527
Cessation of the causative agent in drug-induced AN often results in resolution of AN, and surgical removal of tumors is the mainstay of treatment in malignancy-associated AN.
Substitution of acipimox 250 mg TID
Complete resolution of AN within weeks with no deterioration of lipid profile
View source ↗